Institute of Genomic Medicine, Wenzhou Medical University, Wenzhou, China.
Beijing Institutes of Life Science, Chinese Academy of Sciences, Beijing, China.
Theranostics. 2020 Feb 10;10(7):3035-3048. doi: 10.7150/thno.42559. eCollection 2020.
: Esophageal squamous cell carcinoma (ESCC), one of the leading causes of cancer mortality worldwide, is a heterogeneous cancer with diverse clinical manifestations. However, little is known about the epigenetic heterogeneity and its clinical relevance for this prevalent cancer. : We generated 7.56 Tb single-base resolution whole-genome bisulfite sequencing data for 84 ESCC and paired paraneoplastic tissues. The analysis identified inter- and intratumor DNA methylation (DNAm) heterogeneity, epigenome-wide DNAm alterations together with the functional regulators involved in the hyper- or hypomethylated regions, and their association with clinical features. We then validated the correlation between the methylation level of specific regions and clinical outcomes of 96 ESCC patients in an independent cohort. : ESCC manifested substantial inter- and intratumor DNAm heterogeneity. The high intratumor DNAm heterogeneity was associated with lymph node metastasis and worse overall survival. Interestingly, hypermethylated regions in ESCC were enriched in promoters of numerous transcription factors, and demethylated noncoding regions related to RXR transcription factor binding appeared to contribute to the development of ESCC. Furthermore, we identified numerous DNAm alterations associated with carcinogenesis and lymph node metastasis of ESCC. We also validated three novel prognostic markers for ESCC, including one each in the promoter of , the 3' untranslated region of and the intergenic locus surrounded by several lncRNAs. : This study presents the first population-level resource for dissecting base-resolution DNAm variation in ESCC and provides novel insights into the ESCC pathogenesis and progression, which might facilitate diagnosis and prognosis for this prevalent malignancy.
食管鳞状细胞癌(ESCC)是全球主要的癌症死因之一,是一种具有多种临床表现的异质性癌症。然而,对于这种常见癌症的表观遗传异质性及其临床相关性知之甚少。
我们为 84 例 ESCC 和配对的癌旁组织生成了 7.56 Tb 单碱基分辨率全基因组亚硫酸氢盐测序数据。分析确定了肿瘤内和肿瘤间的 DNA 甲基化(DNAm)异质性、全基因组范围内的表观基因组 DNAm 改变以及涉及超甲基化或低甲基化区域的功能调节剂,及其与临床特征的关联。然后,我们在独立队列的 96 例 ESCC 患者中验证了特定区域的甲基化水平与临床结果之间的相关性。
ESCC 表现出明显的肿瘤内和肿瘤间 DNAm 异质性。高肿瘤内 DNAm 异质性与淋巴结转移和总体生存率降低有关。有趣的是,ESCC 中的高甲基化区域富含许多转录因子的启动子,而与 RXR 转录因子结合相关的去甲基化非编码区域似乎有助于 ESCC 的发生发展。此外,我们确定了许多与 ESCC 发生和淋巴结转移相关的 DNAm 改变。我们还验证了三个用于 ESCC 的新型预后标志物,包括一个位于 基因的启动子中,一个位于 基因的 3'非翻译区,一个位于几个长非编码 RNA 包围的基因间基因座。
本研究首次提供了用于剖析 ESCC 中碱基分辨率 DNAm 变异的人群资源,并提供了 ESCC 发病机制和进展的新见解,这可能有助于该常见恶性肿瘤的诊断和预后。